AI tool decodes unknown proteins to reveal hidden biology

Summary

Proteins are the workhorses of our bodies, made up of chains of molecules called peptides. To understand health and disease, scientists need to read these peptide sequences along with any chemical tags attached to them, known as posttranslational modifications. Usually, identifying these structures requires comparing samples against existing databases of known proteins. But this leaves a major blind spot when a protein or modification has never been mapped before. To solve this, researchers have developed a new artificial intelligence tool called RNovA.

RNovA uses a transformer architecture, which is similar to the technology behind advanced language models, combined with a step-by-step decision process. This design allows the tool to analyze data directly from mass spectrometry, a common laboratory technique used to measure molecules, and figure out the exact peptide sequence from scratch. Impressively, RNovA can discover brand new chemical tags on the fly. It does this without relying on a cheat sheet of known proteins or needing to be retrained for every new experiment.

To prove the algorithm works, the research team tested it on clinical samples from patients with rheumatoid arthritis. RNovA successfully spotted peptides altered by a specific chemical called kynurenine, a finding the team then confirmed using lab-made reference samples. They also tested the tool on a bacterial strain that completely lacks a mapped genetic reference, successfully finding a previously unknown chemical modification.

Why it matters.

This breakthrough acts like a universal translator for the unmapped regions of biology. By allowing scientists to explore uncharted areas of the protein world, tools like RNovA could help uncover the hidden molecular drivers of complex diseases. This deeper understanding is a crucial first step toward developing more precise diagnostics and highly targeted medical treatments in the future.

However, it is important to note that this research is still in its early stages. So far, the tool's accuracy has only been validated on a few specific proof-of-concept examples, including the rheumatoid arthritis samples and a single bacterial strain. Researchers will need to test the algorithm on much larger patient cohorts to fully understand its scale and reliability in everyday clinical research.

From the source

The story in numbers.

Labeled training data or predefined candidate residues required for new PTM discovery (zero-shot): 0
Unannotated glutamic acid modification detected in bacterial strain A1232E: 1

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

Follow your curiosity.

AI tool decodes unknown proteins to reveal hidden biology

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

A little science goes a long way.